VNDA Financial Facts
Research and development: 7.29MCost of sales, product: 6.99M
See Full Income Statement
Cash and cash equivalents: 32.77M
Total current liabilities: 50.68M
See Full Balance Sheet
Vanda Pharma (VNDA) Earnings
|
Expand Research on VNDA
Next EPS Date | 5/1/24 | EPS Growth Rate | -233.3% |
---|---|---|---|
Average EPS % Beat Rate | +35.8% | Revenue Growth Rate | +59,101.9% |
Average % Move 1-Wk after EPS | -3.7% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
5/1/24 | Q124 | N/A | -$0.08 | N/A | N/A | $37M | N/A | N/A | N/A | ||
2/7/24 | Q423 | -$0.04 | -$0.09 | +$0.05 | $45.27M | $37M | N/A | Details | |||
11/1/23 | Q323 | N/A | -$0.04 | N/A | N/A | $44.5M | N/A | N/A | N/A | ||
11/8/23 | Q323 | $0.00 | -$0.04 | +$0.04 | $38.82M | $44.5M | N/A | Details | |||
7/27/23 | Q223 | $0.03 | $0.08 | -$0.05 | $46.06M | $62M | N/A | Details | |||
5/3/23 | Q123 | $0.06 | N/A | N/A | $62.5K | N/A | N/A | Details | |||
2/8/23 | Q422 | $0.12 | $0.08 | +$0.04 | $64.5M | $67.6M | N/A | Details | |||
11/2/22 | Q322 | $0.14 | $0.11 | +$0.03 | $70.1M | $67.9M | = | Details |